PubMed

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C.

Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB Jr.

Ann Intern Med. 1997 Nov 15;127(10):866-74.PMID: 9382364 [PubMed - indexed for MEDLINE]Related articlesFree article

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

Wright M, Grieve R, Roberts J, Main J, Thomas HC; UK Mild Hepatitis C Trial Investigators.

Health Technol Assess. 2006 Jul;10(21):1-113, iii.PMID: 16750059 [PubMed - indexed for MEDLINE]Related articlesFree article

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Related articlesFree article

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL.

Ann Intern Med. 1997 Nov 15;127(10):855-65.PMID: 9382363 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, Bassendine M, Main J, Thomas H.

Gut. 2006 Sep;55(9):1332-8. Epub 2005 Jun 30.PMID: 15994216 [PubMed - indexed for MEDLINE]Related articlesFree article

Hepatitis C: an economic evaluation of extended treatment with interferon.

Shiell A, Brown S, Farrell GC.

Med J Aust. 1999 Aug 16;171(4):189-93.PMID: 10494234 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.PMID: 14974875 [PubMed - indexed for MEDLINE]Related articles

Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness.

Kuehne FC, Bethe U, Freedberg K, Goldie SJ.

Arch Intern Med. 2002 Dec 9-23;162(22):2545-56.PMID: 12456226 [PubMed - indexed for MEDLINE]Related articlesFree article

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.PMID: 15461877 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.

Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ.

JAMA. 2003 Jul 9;290(2):228-37.PMID: 12851278 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.

Shepherd J, Waugh N, Hewitson P.

Health Technol Assess. 2000;4(33):1-67. Review.PMID: 11134916 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.

Aggarwal R, Ghoshal UC, Naik SR.

Natl Med J India. 2002 Nov-Dec;15(6):320-7.PMID: 12540064 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.PMID: 15307866 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group.

Gut. 2003 Mar;52(3):425-32.PMID: 12584228 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C.

Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R.

J Hepatol. 2000 Oct;33(4):651-8.PMID: 11059872 [PubMed - indexed for MEDLINE]Related articles

[Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]

Buti M, Casado MA, Fosbrook L, Esteban R.

Gastroenterol Hepatol. 1998 Apr;21(4):161-8. Spanish. PMID: 9633175 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of combination therapy for hepatitis C: a decision analytic model.

Stein K, Rosenberg W, Wong J.

Gut. 2002 Feb;50(2):253-8.PMID: 11788569 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan.

Pwu RF, Chan KA.

J Formos Med Assoc. 2002 Sep;101(9):632-41.PMID: 12645191 [PubMed - indexed for MEDLINE]Related articles

The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.

Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK.

J Viral Hepat. 2006 Jun;13(6):377-86.PMID: 16842440 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

San Miguel R, Mar J, Cabasés JM, Guillén-Grima F, Buti M.

Aliment Pharmacol Ther. 2003 Mar 15;17(6):765-73.PMID: 12641498 [PubMed - indexed for MEDLINE]Related articlesFree article